Cyclin-Dependent Kinase Inhibitor 2A Human Recombinant, TAT ( p16-INK4a Human, TAT )

Data sheet

Formulation

Lyophilized from a 0.2um filtered concentrated solution in 1xPBS, pH 7.4.

Solubility

It is recommended to reconstitute the lyophilized p16-INK4a in sterile 18M?-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.

Purity

Greater than 95.0% as determined by:(a) Analysis by RP-HPLC.(b) Analysis by SDS-PAGE.

Description

p16-INK4a Human Recombinant is a single, non-glycosylated, polypeptide chain produced in E.coli, containing a total of 168 amino acids, which includes the 156 residues of full-length p16-INK4a and a 13-residue C-terminal TAT peptide (GGYGRKKRRQRRR), havin

Protein Background

Cyclin-dependent kinase inhibitors (CDKIs) are proteins that bind to and inhibit the activity of CDKs. Two major classes of CDK inhibitors have been identified. The p16 family (p15, p16, p18 and p19) binds to and inhibits the activities of CDK4 and CDK6.

Expression host

Escherichia Coli.

Synonyms

Cyclin-dependent kinase 4 inhibitor A, CDK4I, p16-INK4, p16-INK4a, p16INK4A, CDKN-2A, CDKN2, Multiple tumor suppressor 1, MTS1, CMM2, MLM, TP16, p16(INK4), p19.

Reagent Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.

Stability

Lyophilized p16-INK4a although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution p16-INK4a should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended

Amino acid sequence

EPAAGSSMEP SADWLATAAA RGRVEEVRAL LEAGALPNAP NSYGRRPIQV MMMGSARVAE LLLLHGAEPN CADPATLTRP VHDAAREGFL DTLVVLHRAG ARLDVRDAWG RLPVDLAEEL GHRDVARYLR AAAGGTRGSN HARIDAAEGP SDIPDGGYGR KKRRQRRR.